249 related articles for article (PubMed ID: 25655194)
1. The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy.
Wang LD; Rao TN; Rowe RG; Nguyen PT; Sullivan JL; Pearson DS; Doulatov S; Wu L; Lindsley RC; Zhu H; DeAngelo DJ; Daley GQ; Wagers AJ
Leukemia; 2015 Jun; 29(6):1320-30. PubMed ID: 25655194
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.
Merz H; Kaehler C; Hoefig KP; Branke B; Uckert W; Nadrowitz R; Cerny-Reiterer S; Herrmann H; Feller AC; Valent P
Oncotarget; 2010 Jun; 1(2):104-119. PubMed ID: 21297223
[TBL] [Abstract][Full Text] [Related]
3. Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential pre-myelomastocytic leukemia condition.
Panda D; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Sardana R; Chaturvedi A; Rajpal S; Shetty D; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 May; 100(3):331-344. PubMed ID: 32738100
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis.
Krauth MT; Agis H; Aichberger KJ; Simonitsch-Klupp I; Müllauer L; Mayerhofer M; Böhm A; Horny HP; Valent P
Hum Pathol; 2006 Apr; 37(4):439-47. PubMed ID: 16564918
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment options for mast cell activation disease.
Molderings GJ; Haenisch B; Brettner S; Homann J; Menzen M; Dumoulin FL; Panse J; Butterfield J; Afrin LB
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):671-94. PubMed ID: 27132234
[TBL] [Abstract][Full Text] [Related]
6. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
7. Mast cell leukemia.
Georgin-Lavialle S; Lhermitte L; Dubreuil P; Chandesris MO; Hermine O; Damaj G
Blood; 2013 Feb; 121(8):1285-95. PubMed ID: 23243287
[TBL] [Abstract][Full Text] [Related]
8. CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value.
Pardanani A; Reichard KK; Zblewski D; Abdelrahman RA; Wassie EA; Morice Ii WG; Brooks C; Grogg KL; Hanson CA; Tefferi A; Chen D
Leukemia; 2016 Apr; 30(4):914-8. PubMed ID: 26678095
[TBL] [Abstract][Full Text] [Related]
9. CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion.
Moiseeva EP; Leyland ML; Bradding P
Cell Mol Life Sci; 2012 Aug; 69(16):2751-64. PubMed ID: 22438059
[TBL] [Abstract][Full Text] [Related]
10. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
[TBL] [Abstract][Full Text] [Related]
11. Antagonistic regulation by the transcription factors C/EBPα and MITF specifies basophil and mast cell fates.
Qi X; Hong J; Chaves L; Zhuang Y; Chen Y; Wang D; Chabon J; Graham B; Ohmori K; Li Y; Huang H
Immunity; 2013 Jul; 39(1):97-110. PubMed ID: 23871207
[TBL] [Abstract][Full Text] [Related]
12. Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis.
Gülen T; Möller Westerberg C; Lyberg K; Ekoff M; Kolmert J; Bood J; Öhd J; James A; Dahlén SE; Nilsson G; Dahlén B
Clin Exp Allergy; 2017 Jul; 47(7):909-917. PubMed ID: 28258965
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of neoplastic human mast cells by tryptase-immunoelectron microscopy.
Samorapoompichit P; Schernthaner GH; Worda C; Wimazal F; Krauth MT; Sperr WR; Valent P
Histopathology; 2006 Feb; 48(3):247-57. PubMed ID: 16430471
[TBL] [Abstract][Full Text] [Related]
14. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.
Sotlar K; Horny HP; Simonitsch I; Krokowski M; Aichberger KJ; Mayerhofer M; Printz D; Fritsch G; Valent P
Am J Surg Pathol; 2004 Oct; 28(10):1319-25. PubMed ID: 15371947
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
16. Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis.
Anlauf M; Schäfer MK; Schwark T; von Wurmb-Schwark N; Brand V; Sipos B; Horny HP; Parwaresch R; Hartschuh W; Eiden LE; Klöppel G; Weihe E
J Histochem Cytochem; 2006 Feb; 54(2):201-13. PubMed ID: 16116033
[TBL] [Abstract][Full Text] [Related]
17. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
[TBL] [Abstract][Full Text] [Related]
18. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
[TBL] [Abstract][Full Text] [Related]
19. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
[TBL] [Abstract][Full Text] [Related]
20. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
Zheng Y; Nong L; Liang L; Wang W; Li T
Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
